Patents by Inventor Brian C. Austad

Brian C. Austad has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • FATTY ACID AMIDE HYDROLASE INHIBITORS
    Publication number: 20150239912
    Abstract: The present invention provides fatty acid amide hydrolase inhibitors, solid forms thereof, compositions thereof, and methods of making and using the same.
    Type: Application
    Filed: February 25, 2015
    Publication date: August 27, 2015
    Inventors: Brian C. AUSTAD, Louis GRENIER, Michael J. GROGAN, Tao LIU, Priscilla L. WHITE, Theodore A. MARTINOT, Lin-Chen YU
  • Fatty acid amide hydrolase inhibitors
    Patent number: 9034849
    Abstract: The present invention provides fatty acid amide hydrolase inhibitors, solid forms thereof, compositions thereof, and methods of making and using the same.
    Type: Grant
    Filed: February 1, 2011
    Date of Patent: May 19, 2015
    Assignee: Infinity Pharmaceuticals, Inc.
    Inventors: Brian C. Austad, Louis Grenier, Michael J. Grogan, Tao Liu, Ching Kam Lo, Theodore A. Martinot, Lin-Chen Yu
  • Enzymatic Transamination of Cyclopamine Analogs
    Publication number: 20140371456
    Abstract: Provided are processes for the synthesis of amino analogues from ketone starting materials.
    Type: Application
    Filed: April 21, 2014
    Publication date: December 18, 2014
    Inventors: Brian C. Austad, Adilah Bahadoor, Jitendra D. Belani, Somarajannair Janardanannair, Sheldon L. Wallerstein, Gregg F. Keaney, Priscilla L. White, Charles W. Johannes
  • METHODS FOR STEREOSELECTIVE REDUCTION
    Publication number: 20140357868
    Abstract: The invention is directed to a method to reduce a C—C double bond of an enone of a steroidal compound to produce a mixture of ? ketone product and ? ketone product, comprising treating a solution or suspension of the steroidal compound in a solvent with hydrogen gas in the presence of a catalyst and a substituted pyridine.
    Type: Application
    Filed: May 2, 2014
    Publication date: December 4, 2014
    Applicant: INFINITY PHARMACEUTICALS, INC.
    Inventors: Brian C. Austad, Andre Lescarbeau, Lin-Chen Yu
  • Methods for stereoselective reduction
    Patent number: 8716479
    Abstract: The invention is directed to a method to reduce a C—C double bond of an enone of a steroidal compound to produce a mixture of ? ketone product and ? ketone product, comprising treating a solution or suspension of the steroidal compound in a solvent with hydrogen gas in the presence of a catalyst and a substituted pyridine.
    Type: Grant
    Filed: December 24, 2008
    Date of Patent: May 6, 2014
    Assignee: Infinity Pharmaceuticals, Inc.
    Inventors: Brian C. Austad, Andre Lescarbeau, Lin-Chen Yu
  • Enzymatic transamination of cyclopamine analogs
    Patent number: 8703448
    Abstract: The invention relates to the preparation of amino-cyclopamines by the enzymatic transamination of a corresponding keto-cyclopamines in the presence of a cofactor and an amino donor.
    Type: Grant
    Filed: July 1, 2011
    Date of Patent: April 22, 2014
    Assignee: Infinity Pharmaceuticals, Inc.
    Inventors: Brian C. Austad, Adilah Bahadoor, Jitendra D. Belani, Somarajannair Janardanannair, Charles W. Johannes, Gregg F. Keaney, Priscilla L. White, Sheldon L. Wallerstein
  • Ansamycin formulations and methods of use thereof
    Patent number: 8357676
    Abstract: Provided herein, inter alia, are solid forms of geldanamycin analogs, pharmaceutical compositions comprising a geldanamycin analog and a crystallization inhibitor, methods of making and using such compositions. Additionally, provided are methods for the treatment of cancer, a neoplastic disease state and/or a hyperproliferative disorder, and methods of inhibiting Heat Shock Protein 90 (“Hsp90”).
    Type: Grant
    Filed: August 20, 2008
    Date of Patent: January 22, 2013
    Assignee: Infinity Discovery, Inc.
    Inventors: Brian C. Austad, Louis Grenier, Edward B. Holson, John J. Lee, Roger H. Pak, James R. Porter, James L. Wright
  • Ansamycin formulations and methods of use thereof
    Patent number: 8283343
    Abstract: Amorphous, polymorphic, and solvated forms of 17-amino geldanamycin are disclosed. These compounds are particularly useful for the treatment of cancer, a neoplastic disease state and/or a hyperproliferative disorder, and inhibiting Heat Shock Protein 90 (“Hsp90”).
    Type: Grant
    Filed: August 20, 2008
    Date of Patent: October 9, 2012
    Assignee: Infinity Pharmaceuticals Inc.
    Inventors: Brian C. Austad, Louis Grenier, Edward B. Holson, John J. Lee, Roger H. Pak, James R. Porter, James L. Wright
  • Enzymatic Transamination of Cyclopamine Analogs
    Publication number: 20120083607
    Abstract: Provided are processes for the synthesis of amino analogues from ketone starting materials.
    Type: Application
    Filed: July 1, 2011
    Publication date: April 5, 2012
    Applicant: Infinity Pharmaceuticals, Inc.
    Inventors: Brian c. Austad, Adilah Bahadoor, Jitendra D. Belani, Somarajannair Janardanannair, Charles W. Johannes, Gregg F. Keaney, Priscilla L. White, Sheldon L. Wallerstein
  • Transfer Hydrogenation of Cyclopamine Analogs
    Publication number: 20120065399
    Abstract: Provided herein is a process for the transfer-hydrogenation of ketone analogs of members of the jervine type of Veratrum alkaloids, such as cyclopamine. Also provided herein are novel ruthenium transfer-hydrogenation catalysts.
    Type: Application
    Filed: September 14, 2011
    Publication date: March 15, 2012
    Applicant: INFINITY PHARMACEUTICALS, INC.
    Inventors: Daniel G. Genov, Brian C. Austad, Brian H. White
  • Transfer Hydrogenation of Cyclopamine Analogs
    Publication number: 20120065400
    Abstract: Provided herein is a process for the transfer-hydrogenation of ketone analogs of members of the jervine type of Veratrum alkaloids, such as cyclopamine. Also provided herein are novel ruthenium transfer-hydrogenation catalysts.
    Type: Application
    Filed: September 14, 2011
    Publication date: March 15, 2012
    Applicant: INFINITY PHARMACEUTICALS, INC.
    Inventors: Daniel G. Genov, Brian C. Austad, Brian H. White
  • FATTY ACID AMIDE HYDROLASE INHIBITORS
    Publication number: 20110201574
    Abstract: The present invention provides fatty acid amide hydrolase inhibitors, solid forms thereof, compositions thereof, and methods of making and using the same.
    Type: Application
    Filed: February 1, 2011
    Publication date: August 18, 2011
    Inventors: Brian C. AUSTAD, Louis Grenier, Michael J. Grogan, Tao Liu, Ching Kam Lo, Theodore A. Martinot, Lin-Chen Yu
  • Ansamycin formulations and methods of use thereof
    Patent number: 7947670
    Abstract: Provided herein, inter alia, are solid forms of geldanamycin analogs, pharmaceutical compositions comprising a geldanamycin analog and a crystallization inhibitor, methods of making and using such compositions. Additionally, provided are methods for the treatment of cancer, a neoplastic disease state and/or a hyperproliferative disorder, and methods of inhibiting Heat Shock Protein 90 (“Hsp90”).
    Type: Grant
    Filed: December 11, 2007
    Date of Patent: May 24, 2011
    Assignee: Infinity Pharmaceuticals Inc.
    Inventors: Brian C. Austad, Louis Grenier, Edward B. Holson, John J. Lee, Roger H. Pak, James R. Porter, James L. Wright
  • METHODS FOR STEREOSELECTIVE REDUCTION
    Publication number: 20110009442
    Abstract: The invention is directed to a method to reduce a C—C double bond of an enone of a steroidal compound to produce a mixture of ? ketone product and ? ketone product, comprising treating a solution or suspension of the steroidal compound in a solvent with hydrogen gas in the presence of a catalyst and a substituted pyridine.
    Type: Application
    Filed: December 24, 2008
    Publication date: January 13, 2011
    Inventors: Brian C. Austad, Andre Lescarbeau, Lin-Chen Yu
  • Ansamycin formulations and methods of use thereof
    Publication number: 20090069281
    Abstract: Provided herein, inter alia, are solid forms of geldanamycin analogs, pharmaceutical compositions comprising a geldanamycin analog and a crystallization inhibitor, methods of making and using such compositions. Additionally, provided are methods for the treatment of cancer, a neoplastic disease state and/or a hyperproliferative disorder, and methods of inhibiting Heat Shock Protein 90 (“Hsp90”).
    Type: Application
    Filed: August 20, 2008
    Publication date: March 12, 2009
    Inventors: Brian C. Austad, Louis Grenier, Edward B. Holson, John J. Lee, Roger H. Pak, James R. Porter, James L. Wright
  • Ansamycin formulations and methods of use thereof
    Publication number: 20090062528
    Abstract: Provided herein, inter alia, are solid forms of geldanamycin analogs, pharmaceutical compositions comprising a geldanamycin analog and a crystallization inhibitor, methods of making and using such compositions. Additionally, provided are methods for the treatment of cancer, a neoplastic disease state and/or a hyperproliferative disorder, and methods of inhibiting Heat Shock Protein 90 (“Hsp90”).
    Type: Application
    Filed: August 20, 2008
    Publication date: March 5, 2009
    Inventors: Brian C. Austad, Louis Grenier, Edward B. Holson, John J. Lee, Roger H. Pak, James R. Porter, James L. Wright
  • Ansamycin formulations and methods of use thereof
    Publication number: 20080221077
    Abstract: Provided herein, inter alia, are solid forms of geldanamycin analogs, pharmaceutical compositions comprising a geldanamycin analog and a crystallization inhibitor, methods of making and using such compositions. Additionally, provided are methods for the treatment of cancer, a neoplastic disease state and/or a hyperproliferative disorder, and methods of inhibiting Heat Shock Protein 90 (“Hsp90”).
    Type: Application
    Filed: December 11, 2007
    Publication date: September 11, 2008
    Inventors: Brian C. Austad, Louis Grenier, Edward B. Holson, John J. Lee, Roger H. Pak, James R. Porter, James L. Wright